INTERNATIONAL MYELOMA FOUNDATION for INTERNATIONAL MYELOMA FOUNDATION
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Aug 6, 2025 | $38,492 | Replaced |
| 2nd Quarter - Amendment | Aug 22, 2025 | $25,123 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
H.R. 9747, (P.L. 118-83) the FY2025 Continuing Appropriations and Extensions Act: Cancer Research, Appropriations: Cancer Research, NIH, CDC, NCI, DoD, ARPA-H
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIELLE DOHENY | — |
Health Issues HCR
Access Issues, Cancer Drug Parity Act, Step Therapy Reform
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIELLE DOHENY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.